U.S. markets closed
  • S&P Futures

    +2.50 (+0.06%)
  • Dow Futures

    +24.00 (+0.07%)
  • Nasdaq Futures

    +21.50 (+0.16%)
  • Russell 2000 Futures

    +1.20 (+0.05%)
  • Crude Oil

    +0.53 (+0.82%)
  • Gold

    +2.30 (+0.13%)
  • Silver

    +0.15 (+0.56%)

    +0.0098 (+0.82%)
  • 10-Yr Bond

    +0.0160 (+1.02%)
  • Vix

    -1.70 (-9.24%)

    +0.0131 (+0.94%)

    -0.5010 (-0.46%)

    -466.27 (-0.80%)
  • CMC Crypto 200

    +44.29 (+3.08%)
  • FTSE 100

    +53.54 (+0.76%)
  • Nikkei 225

    +26.42 (+0.09%)

Free Research Reports on DexCom and Three More Medical Research Stocks

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Stock Research Monitor: CGIX, CHEK, and EXAS

LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration. Today's research on WallStEquities.com is focused on Cancer Genetics Inc. (NASDAQ: CGIX), Check-Cap Ltd (NASDAQ: CHEK), DexCom Inc. (NASDAQ: DXCM), and Exact Sciences Corp. (NASDAQ: EXAS). These stocks belong to the Medical Laboratories and Research category, which is very small from a dividend perspective. Companies in this group focus on performing various tests on patients that give them information on patients' health. All you have to do is sign up today for this free limited time offer by clicking the link below.


Cancer Genetics

On Wednesday, shares in Rutherford, New Jersey-based Cancer Genetics Inc. recorded a trading volume of 42,843 shares. The stock ended the session 0.31% lower at $0.90. The Company's shares are trading 5.05% below their 50-day moving average. Moreover, shares of Cancer Genetics, which develops, commercializes, and provides molecular and biomarker-based tests and services in the US, Europe, and Asia, have a Relative Strength Index (RSI) of 46.69. Get the full research report on CGIX for free by clicking below at:



Isfiya, Israel-based Check-Cap Ltd's stock closed the day 0.24% lower at $4.09 with a total trading volume of 121,473 shares. The Company's shares have advanced 7.07% in the previous three months. The stock is trading 15.60% below its 50-day moving average. Additionally, shares of Check-Cap, which engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel, have an RSI of 49.28. Today's complimentary research report on CHEK is accessible at:



Shares in San Diego, California headquartered DexCom Inc. recorded a trading volume of 802,084 shares. The stock ended yesterday's trading session 2.71% higher at $102.71. The Company's shares have advanced 8.10% in the past month, 44.74% in the previous three months, and 43.67% over the past year. The stock is trading above its 50-day and 200-day moving averages by 12.53% and 54.77%, respectively. Furthermore, shares of DexCom, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 67.17.

On July 02nd, 2018, research firm Raymond James upgraded the Company's stock rating from ‘Market Perform' to ‘Outperform'.

On July 03rd, 2018, DexCom announced that it plans to release its Q2 2018 financial results after market close on August 01st, 2018. Management will hold a conference call starting at 4:30 p.m. ET that same day to review the Company's performance. Sign up for free on Wall St. Equities and claim the latest report on DXCM at:


Exact Sciences

Madison, Wisconsin headquartered Exact Sciences Corp.'s stock finished Wednesday's session 0.18% higher at $62.50 with a total trading volume of 1.21 million shares. The Company's shares have advanced 47.54% over the previous three months and 64.78% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.69% and 19.81%, respectively. Additionally, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, an RSI of 51.77.

On July 09th, 2018, Exact Sciences announced plans to release its Q2 2018 financial results after the close of the US financial markets onAugust 01st, 2018. Following the release, management will host a webcast and conference call at 5:00 p.m. ETto discuss the results and business progress. The live webcast can be accessedon the Company's website. See the free research coverage on EXAS at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities